Novel Therapies Show Early Promise in Advanced Gastroesophageal Cancers
Results of two early-phase trials offered a glimpse of promising new agents in the pipeline for advanced gastroesophageal cancer. In a phase II study, incorporating an investigational PD-1 inhibitor and anti-T-cell immunoglobulin and ITM domain (TIGIT) monoclonal antibody into standard first-line chemotherapy showed promising activity in advanced gastroesophageal adenocarcinoma, reported Yelena Janjigian, MD, from Memorial […]
Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer
MADRID — Including pembrolizumab (Keytruda) in the first-line treatment of metastatic HER2-positive gastric or gastroesophageal cancer improved progression-free survival (PFS), but potential harm was seen in PD-L1-negative patients, the randomized KEYNOTE-811 trial showed. In patients receiving standard chemotherapy plus trastuzumab, median PFS improved from 8.1 months with placebo to 10.0 months with pembrolizumab (HR 0.73, […]
Modest Survival Gain in Gastric/GEJ Cancer With Chemo Plus Pembrolizumab
Adding pembrolizumab (Keytruda) to chemotherapy modestly improved survival in unresectable/metastatic gastric or gastroesophageal junction (GEJ) cancer, a randomized trial showed. Median overall survival (OS) improved from 11.5 months with chemotherapy alone to 12.9 months with the addition of the immune checkpoint inhibitor. Median progression-free survival (PFS) improved from 5.6 months to 6.9 months. Landmark survival […]